The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea

Update: 2014-04-09

Description

Patients with Pulmonary Arterial Hypertension share similarities with those with myeloproliferative disorders. Hydroxyurea is used routinely in this group of patients and works by decreasing hematopoietic progenitors and peripheral counts. NHLBI researcher, Dr. Ronan Desmond, discusses a hypothesis that hydroxyurea could potentially improve hemodynamic parameters in PAH. He also discusses the pre-clinical work that led to this protocol’s conception and outlines details of its upcoming clinical trial.

Comments

In Channel

Diuretics in PAH

2014-05-1449:55

Working with Social Workers to Enhance the PH Team

2014-05-0748:07

The Role of the Respiratory Therapist in the Treatment of Pulmonary Hypertension Patients

2014-04-3058:41

Understanding Compassion Fatigue

2014-04-2331:14

The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea

2014-04-0928:08

Pulmonary Hypertension in Schistosomiasis: An Overview

2014-04-0201:09:49

New Quality Indicator Set for Systemic Sclerosis

2014-03-2632:19

Design and Validation of a Novel EPC Microfluidic Capture Chip and its Application in Patients with PAH

2014-03-1942:05

Caveolin-1 Expression During the Progression of Pulmonary Hypertension

2013-11-1135:09

17-Beta Estradiol Attenuates Hypoxic Pulmonary Hypertension via Estrogen Receptor-mediated Effects

2013-11-1049:58

00:00

The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea

#box-pro-ellipsis-176173376541318{-webkit-line-clamp:2;}The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea

The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea

Ronan Desmond, MD

The Treatment of Pulmonary Arterial Hypertension with the Anti-proliferative Agent Hydroxyurea